Blauvelt Consulting

Nov 14, 2024 | link.springer.com | Blauvelt Consulting |Lake Oswego

AbstractAtopic dermatitis (AD) is associated with itch, skin pain, sleep disturbances, and diminished quality of life (QoL). Ruxolitinib (Janus kinase [JAK] 1/JAK2 inhibitor) cream demonstrated efficacy and safety in adults and adolescents with mild-to-moderate AD in two phase III studies (TRuE-AD1/TRuE-AD2). In TRuE-AD1/TRuE-AD2, significant improvements in itch were observed as early as 12 h following application of ruxolitinib cream.

Jul 31, 2024 | jamanetwork.com | Andrew Blauvelt |Blauvelt Consulting |Lake Oswego |Curdin Conrad

Extending Maintenance Dosing Intervals for Guselkumab in the Treatment of Patients With Psoriasis 16-Week vs 8-Week Guselkumab Dosing in Super Responders for Control of Psoriasis Kilian Eyerich, MD; Khusru Asadullah, MD; Andreas Pinter, MD; Peter Weisenseel, MD; Kristian Reich, MD; Carle Paul, MD; Robert Sabat, MD; Kerstin Wolk, PhD; Stefanie Eyerich, PhD; Felix Lauffer, MD; Julianty Angsana, PhD; Friedemann J. H.